Geron Corporation

 

Geron is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.

Geron is developing first-in-class therapies for the treatment of cancer. The company is advancing a telomerase inhibitor and a peptide drug conjugate to penetrate the blood-brain barrier through multiple Phase 2 clinical trials in different indications. While not focused on ALS, this research has important implications for ALS.

More information about specific research underway can be seen at their website.

 

 

 

 

 

 

 

 

 

 

ALS Survey

ALS WORLDWIDE is conducting a comprehensive survey as part of a two-year research study of Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease). The information collected will help to identify clusters, patterns and suspected causes of ALS in the world.

You can participate by completing one of the following questionnaires through Survey Methods at the following links:

ALS Patient - ALS PATIENT SURVEY
Close Relative or Caregiver -
DECEASED PATIENT SURVEY
General Public - GENERAL SURVEY